Table 1.

Prognostic ability of clinical factors and molecular alterations

RFSOS
nEventsHRPnEventsHRP
Clinical (all patients)a
Ki67 score > 15105600.9150.772108521.1790.623
Node positive104601.6640.068107521.5340.147
Age > 50 y105600.9320.790108520.8720.630
Postmenopausal105600.6810.138108520.7110.221
Neoadjuvant taxane105601.2550.390108521.1570.625
Genes (TNBC only)
MCL1 = amp64400.6200.13067360.6200.140
MYC = amp64401.3700.40067361.7800.084
PIK3CA = amp/mut64400.5300.38067360.3000.210
BRCA1 = trunc/mut64401.7000.26067362.5000.041
RB1 = del/trunc64400.9100.85067360.7600.660
PTEN = del/trunc/mut64400.5700.28067360.1400.030
JAK2 = amp64403.3600.00667364.1600.002
Pathways (TNBC only)
Cell-cycle altered64400.5800.10067360.5600.110
DNA repair altered64401.5700.25367361.8900.090
PI3K/mTOR altered64400.8130.54067360.6600.280
Ras/MAPK altered64401.0000.98067360.8600.755
GFR amplified64401.0300.92067361.2200.600
Gene signatures (TNBC only)
MEK signature = int/high79422.1200.03581373.1700.004
TGF-β signature = int/high79421.2500.50081371.5700.207

NOTE: P ≤ 0.05 (significant) or P ≤ 0.1 (statistical trend) defined in bold italics.

  • aClinical data analysis of clinically defined TNBC includes 7 samples later identified as HER2 amplified by NGS.